JustCare

Tag: AstraZeneca

  • President Trump’s executive order won’t lower drug prices

    President Trump’s executive order won’t lower drug prices

    President Trump finally issued his fourth prescription drug executive order, related to pricing drugs at the average of what other wealthy countries pay. Much like his first three executive orders, it does precious little. While it appears to take on high drug costs, the executive order language is so weak that it is not likely to lower drug prices.

    First, President Trump’s executive order only applies to the 20 percent of the population with Medicare. It does not apply to working people or children. Even for people with Medicare, the executive order includes language that allows for extreme delay in implementation, if in fact it will ever come to pass.

    While the executive order applies to drugs administered in a physician’s office as well as those purchased at a pharmacy, it targets a small number of drugs. It only applies to “some high-cost drugs and biological products.” Moreover, the executive order is only to “test” the value of pricing these drugs at a price similar to other wealthy countries.

    The executive order does not try to regulate the price of drugs developed with federal research or funding. In short, President Trump has not acted to lower or even freeze prescription drug prices, although he has promised to do so. And, he has said nothing about pharmaceutical company drug price hikes, which are happening.

    For example, Noam Levy reports for the LA times that AstraZeneca has exercised its monopoly pricing power to hike up its prices dramatically this year. AstraZeneca’s drug prices have risen far faster than inflation, up as much as six percent when inflation is at about one percent. At the same time, it has benefited from $1.2 billion in taxpayer dollars to develop a COVID-19 vaccine.

    AstraZeneca is not alone. Many other pharmaceutical companies have raised the prices of some of their best-selling drugs far more than inflation. AbbVie raised the price of Humira by 7.4 percent, along with the price of other drugs. GlaxoSmithKline also raised some drug prices significantly.

    The leaders of other wealthy nations ensure medicines are affordable for everyone by negotiating prescription drug prices. President Trump has not even required the pharmaceutical companies that received hundreds of millions of taxpayer dollar to develop a COVID-19 vaccine to commit to charging a fair price for their vaccine. How many millions of Americans will end up without a vaccine and remain at high risk for getting COVID-19 because of the vaccine’s cost?

    Here’s more from Just Care:
  • AstraZeneca CEO calls excessive price hikes modest

    AstraZeneca CEO calls excessive price hikes modest

    StatNews reports that AstraZeneca CEO, Pascal Soriot, already has hiked prescription drug prices excessively this year on many of the company’s drugs between five and ten (9.9 to be precise) percent. Yet, on a recent investor call, he said that these price increases were “modest.” And, he claimed that 2018 AstraZeneca prices increases were between 1 and 3 percent, in line with inflation.

    Yes, we are living in a world where 1 to 3 percent is really 5 to 10 percent and excessive is modest. When questioned, an AstraZeneca spokesperson claimed that Soriot was only speaking about some of its drugs, not all of them. And, some drugs only did see small price hikes. Of course, some is not all.

    Congress has given pharmaceutical companies with patented products the freedom to increase their prices at will, as much as they think Congress and insurers will tolerate. And, they have. So, Soriot might believe that drug price increases that are between five and ten percent are modest, given that they could be 50 and 100 percent or even 500 and 1,000 percent.

    If Soriot was trying to show that he understood the public’s concern with high prescription drug prices, he failed. He intended to support Trump when he said that AstraZeneca would not raise its drug prices again this year. But, he should be called to task for even suggesting that AstraZeneca is trying to serve the public good when his company charges excessive prices for its drugs and has already raised prices way higher than inflation this year.

    Here’s more from Just Care: